The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions - 97(2021), 6 vom: 01. Mai, Seite 1221-1229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vogt, Joshua C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NDF7JZ4M3 |
|---|
| Anmerkungen: |
Date Completed 11.10.2021 Date Revised 11.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ccd.29089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31215903X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31215903X | ||
| 003 | DE-627 | ||
| 005 | 20231225143818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccd.29089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM31215903X | ||
| 035 | |a (NLM)32638540 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vogt, Joshua C |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2021 | ||
| 500 | |a Date Revised 11.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a drugs/pharmacotherapy | |
| 650 | 4 | |a peripheral artery disease | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Manning, Patrick G |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Aronow, Herbert D |e verfasserin |4 aut | |
| 700 | 1 | |a Chilton, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Cigarroa, Joaquin E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |d 1999 |g 97(2021), 6 vom: 01. Mai, Seite 1221-1229 |w (DE-627)NLM101487487 |x 1522-726X |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2021 |g number:6 |g day:01 |g month:05 |g pages:1221-1229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccd.29089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2021 |e 6 |b 01 |c 05 |h 1221-1229 | ||